Literature DB >> 1360879

CD4-independent binding of HIV-1 to the B lymphocyte receptor CR2 (CD21) in the presence of complement and antibody.

D C Montefiori1, J Zhou, D I Shaff.   

Abstract

Complement and antibody contribute to infection-enhancement and possible expanded cellular tropism of HIV-1 in vitro through a process requiring complement receptors. Until now, however, the ability of HIV-1 to bind complement receptors has not been documented or characterized. We investigated whether antibody and complement permitted HIV-1 to bind to the B lymphocyte receptor, CR2 (CD21), in an effort to learn more about infection-enhancement, and also because CR2 can mediate B cell proliferation and antigen localization in lymphoid organs in other systems. HIV-1 incubated with antibody and fresh human serum as a source of complement bound approximately 10-fold greater to cells expressing CR2 than to HIV-1-permissive cells lacking this receptor. A similar effect was observed using cells which expressed CR2 but no CD4. This binding was minimal in heat-inactivated and C3-deficient sera, and was significantly reduced by the anti-CR2 MoAb, OKB7, but not by the anti-CD4 MoAb, OKT4a. Thus, complement and antibody acted in concert to facilitate the binding of HIV-1 to CR2 independently of CD4. CD4-independent binding of HIV-1 to CR2 was not sufficient to produce infection in Raji-3 cells. Titres of antibodies mediating CR2 binding correlated with antibody titres as measured by immunofluorescence (P < 0.01) and infection-enhancement (P < 0.05) but were discordant with titres of neutralizing antibodies, a result consistent with the utilization of CR2 for enhanced infection of cells. The ability of complement and antibody to facilitate the binding of HIV-1 to CR2 in the absence of CD4 provides new insights into mechanisms of HIV-1-induced immunopathogenesis and infection-enhancement.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1360879      PMCID: PMC1554591          DOI: 10.1111/j.1365-2249.1992.tb05855.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  48 in total

Review 1.  The immunopathogenesis of HIV infection.

Authors:  Z F Rosenberg; A S Fauci
Journal:  Adv Immunol       Date:  1989       Impact factor: 3.543

Review 2.  Regulatory pathways governing HIV-1 replication.

Authors:  B R Cullen; W C Greene
Journal:  Cell       Date:  1989-08-11       Impact factor: 41.582

3.  Infection of the HTLV-II-bearing T-cell line C3 with HTLV-III/LAV is highly permissive and lytic.

Authors:  D C Montefiori; W M Mitchell
Journal:  Virology       Date:  1986-12       Impact factor: 3.616

4.  HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex.

Authors:  M Robert-Guroff; M Brown; R C Gallo
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

5.  HTLV-III/LAV viral antigens in lymph nodes of homosexual men with persistent generalized lymphadenopathy and AIDS.

Authors:  K Tenner-Racz; P Racz; M Bofill; A Schulz-Meyer; M Dietrich; P Kern; J Weber; A J Pinching; F Veronese-Dimarzo; M Popovic
Journal:  Am J Pathol       Date:  1986-04       Impact factor: 4.307

6.  Human follicular dendritic cells express CR1, CR2, and CR3 complement receptor antigens.

Authors:  M Reynes; J P Aubert; J H Cohen; J Audouin; V Tricottet; J Diebold; M D Kazatchkine
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

7.  Complement-mediated antibody-dependent enhancement of HIV-1 infection requires CD4 and complement receptors.

Authors:  W E Robinson; D C Montefiori; W M Mitchell
Journal:  Virology       Date:  1990-04       Impact factor: 3.616

8.  Infection with the human immunodeficiency virus (HIV) is associated with an in vivo increase in B lymphocyte activation and immaturity.

Authors:  O Martínez-Maza; E Crabb; R T Mitsuyasu; J L Fahey; J V Giorgi
Journal:  J Immunol       Date:  1987-06-01       Impact factor: 5.422

9.  Antibody-dependent enhancement of human immunodeficiency virus type 1 infection.

Authors:  W E Robinson; D C Montefiori; W M Mitchell
Journal:  Lancet       Date:  1988-04-09       Impact factor: 79.321

10.  High prevalence of antibodies to acquired immune deficiency syndrome (AIDS)-associated retrovirus (ARV) in AIDS and related conditions but not in other disease states.

Authors:  L S Kaminsky; T McHugh; D Stites; P Volberding; G Henle; W Henle; J A Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

View more
  5 in total

Review 1.  Role of complement and Fc receptors in the pathogenesis of HIV-1 infection.

Authors:  D C Montefiori
Journal:  Springer Semin Immunopathol       Date:  1997

2.  An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys.

Authors:  K A Reimann; J T Li; G Voss; C Lekutis; K Tenner-Racz; P Racz; W Lin; D C Montefiori; D E Lee-Parritz; Y Lu; R G Collman; J Sodroski; N L Letvin
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

3.  Comparison of human immunodeficiency virus (HIV)-specific infection-enhancing and -inhibiting antibodies in AIDS patients.

Authors:  Ramu A Subbramanian; Jingwu Xu; Emil Toma; Richard Morisset; Eric A Cohen; José Menezes; Ali Ahmad
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

4.  Increased adhesion as a mechanism of antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus infection.

Authors:  O Lund; J Hansen; A M Søorensen; E Mosekilde; J O Nielsen; J E Hansen
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

5.  V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.

Authors:  Lautaro G Perez; David R Martinez; Allan C deCamp; Abraham Pinter; Phillip W Berman; Donald Francis; Faruk Sinangil; Carter Lee; Kelli Greene; Hongmei Gao; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Jaranit Kaewkungwal; Punnee Pitisuttithum; James Tartaglia; Robert J O'Connell; Merlin L Robb; Nelson L Michael; Jerome H Kim; Peter Gilbert; David C Montefiori
Journal:  PLoS One       Date:  2017-07-05       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.